Active ingredients: rituximab
What it is used for
MABTHERA SC is indicated for treatment of patients with: - CD20 positive, previously untreated, Stage III/IV follicular, B-Cell non-Hodgkin's lymphoma, - CD20 positive, relapsed or refractory low grade or follicular, B-cell non-Hodgkin's lymphoma, - CD 20 positive, diffuse large B-cell non-Hodgkin's lymphoma, in combination with chemotherapy.
How to take it
The way to take this medicine is: Subcutaneous. This medicine is injected, usually with a short needle or pen-like device, into the fat just beneath the skin.
- Store at 2 to 8 degrees Celsius
- Protect from Light
- Shelf lifetime is 30 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Clear to opalescent, colourless to yellowish solution
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Is this medicine subsidised?
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on April 1, 2019. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Pregnant or planning a pregnancy?
For the active ingredient rituximab
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems